Study guide

4.3 Amenorrhea Evaluation: Primary & Secondary Etiologies

WHNP-BC Women's Health Nurse Practitioner Study Guide Exam

Track your progress as you read

Finished sections get a check mark.

1 Introduction: About the WHNP-BC Exam

WHNP-BC Exam Facts, Blueprint & Study Plan

2 Chapter 1: Well-Woman Care, Assessment & Gynecologic Screening

1.1 Well-Woman Health Maintenance & Routine Screening Across the Lifespan 1.2 Comprehensive Health History & Physical Examination (Female and Male) 1.3 Cervical Cancer Screening & ASCCP Risk-Based Management Guidelines 1.4 Breast Health Assessment, Diagnostic Imaging & Breast Cancer Screening

3 Chapter 2: Vulvovaginal Infections, STIs & HIV Prevention

2.1 Vulvovaginitis: Bacterial Vaginosis, Candidiasis & Trichomoniasis 2.2 Sexually Transmitted Infections: Chlamydia, Gonorrhea, Syphilis & Pelvic Inflammatory Disease 2.3 Viral STIs & Chronic Vulvar Dermatoses (HSV, HPV, Lichen Sclerosus & Lichen Planus) 2.4 HIV Prevention (PrEP & PEP), Viral Hepatitis, Mycoplasma genitalium & Ectoparasites

4 Chapter 3: Gynecologic Disorders, Pelvic Pain & Gynecologic Cancers

3.1 Abnormal Uterine Bleeding & the FIGO PALM-COEIN Classification 3.2 Uterine Leiomyomas, Adenomyosis & Endometrial and Cervical Polyps 3.3 Dysmenorrhea, Endometriosis & Chronic Pelvic Pain Management 3.4 Benign Pelvic Masses, Pelvic Organ Prolapse & Urinary Incontinence 3.5 Gynecologic Malignancies: Endometrial, Ovarian, Cervical, Vulvar & Vaginal Cancers

5 Chapter 4: Reproductive Physiology, Endocrinology & Infertility

4.1 Reproductive Anatomy, Puberty, the Menstrual Cycle & Müllerian Anomalies 4.2 Polycystic Ovary Syndrome (PCOS) & Hyperandrogenic Disorders 4.3 Amenorrhea Evaluation: Primary & Secondary Etiologies 4.4 Infertility Workup, Ovulation Induction & Assisted Reproductive Technologies

6 Chapter 5: Contraception, Family Planning & Unintended Pregnancy

5.1 Long-Acting Reversible Contraception (LARC): IUDs & Subdermal Implants 5.2 Hormonal Contraceptives: Combined & Progestin-Only Methods 5.3 Emergency Contraception, Barrier Methods & Fertility Awareness-Based Methods 5.4 CDC U.S. Medical Eligibility Criteria (US MEC) & Permanent Sterilization 5.5 Unintended Pregnancy: Options Counseling, Medication & Procedural Abortion

7 Chapter 6: Perimenopause, Menopause & Postmenopausal Health

6.1 Menopausal Transition Physiology, Vasomotor Symptoms & Clinical Staging (STRAW+10) 6.2 Menopausal Hormone Therapy (MHT): Indications, Regimens & Contraindications 6.3 Genitourinary Syndrome of Menopause (GSM) & Postmenopausal Osteoporosis

8 Chapter 7: Sexual Health, Male Reproductive Health & LGBTQ+ Care

7.1 Female Sexual Function, Sexual Dysfunction & LGBTQ+ Sexual Health 7.2 Male Sexual & Reproductive Health: STIs, Infertility, Contraception & Sexual Dysfunction

9 Chapter 8: Preconception, Fetal Development & Normal Antepartum Care

8.1 Preconception Counseling, Risk Assessment & Teratogen Exposure 8.2 Early Pregnancy Diagnosis, Gestational Dating & Initial Prenatal Evaluation 8.3 Embryonic & Fetal Development, the Placenta, Fetal Circulation & Amniotic Fluid 8.4 Routine Antepartum Surveillance, Nutritional Needs & Weight Gain Guidelines 8.5 Management of Common Discomforts & Physiologic Changes in Pregnancy

10 Chapter 9: Antepartum Complications I: Hypertension, Diabetes, Bleeding & Preterm Birth

9.1 Hypertensive Disorders of Pregnancy & Preeclampsia Management 9.2 Gestational Diabetes Mellitus: Screening, Glycemic Targets & Management 9.3 Bleeding in Pregnancy: Spontaneous Abortion, Ectopic Pregnancy & Placental Disorders 9.4 Preterm Labor, PPROM & Cervical Insufficiency

11 Chapter 10: Antepartum Complications II: Infections, Medical Disorders & Fetal Conditions

10.1 Infections in Pregnancy: CMV, Parvovirus, Varicella, Rubella, Toxoplasmosis, Listeria, GBS & HIV 10.2 Maternal Medical Disorders in Pregnancy: Pregestational Diabetes, Epilepsy, Thrombocytopenia, Obesity & Cardiac Disease 10.3 Gestational Trophoblastic Disease, Recurrent Loss, Stillbirth & Perinatal Bereavement 10.4 Multiple Gestation, Fetal Growth Disorders, Amniotic Fluid Abnormalities, Malpresentation & Postterm Pregnancy 10.5 Rh(D) Alloimmunization & Hemolytic Disease of the Fetus and Newborn

12 Chapter 11: Intrapartum Principles & Fetal Surveillance

11.1 Electronic Fetal Monitoring (EFM): Baseline, Variability, Decelerations & Categories 11.2 Labor Assessment, Stages of Labor & Labor Dystocia 11.3 Trial of Labor After Cesarean (TOLAC) & Intrapartum Emergencies

13 Chapter 12: Postpartum Management, Lactation & Puerperal Complications

12.1 Postpartum Involution, Physical Recovery & Routine Puerperal Care 12.2 Postpartum Hemorrhage: The 4 Ts, Uterotonic Pharmacotherapy & Emergency Protocols 12.3 Puerperal Infections & Postpartum Mood Disorders 12.4 Physiology of Lactation, Common Breastfeeding Challenges & Infant Feeding 12.5 Other Puerperal Complications: Hematomas, Urinary Retention, Hemorrhoids, Postpartum Hypertension & Warning Signs

14 Chapter 13: Primary Care: Cardiovascular, Thromboembolic, Respiratory & HEENT Conditions

13.1 Hypertension & Cardiovascular Disease in Women: Gender-Specific Presentations 13.2 Dyslipidemia & ASCVD Risk: The 2026 ACC/AHA Guideline 13.3 Venous Thromboembolism in Women: Risk, Diagnosis, Treatment & Prevention in Pregnancy 13.4 Respiratory Conditions in Women: Asthma Management & Respiratory Infections 13.5 HEENT & Upper Respiratory Conditions: Conjunctivitis, Rhinitis, Pharyngitis, Sinusitis, Otitis & the Common Cold

15 Chapter 14: Primary Care: Endocrine, Metabolic & Gastrointestinal Disorders

14.1 Type 2 Diabetes Mellitus & Metabolic Syndrome in Women 14.2 Obesity, Weight Management & Healthy Lifestyle Counseling 14.3 Thyroid Disorders: Hypothyroidism, Hyperthyroidism & Postpartum Thyroiditis 14.4 Gastrointestinal Conditions: GERD, Irritable Bowel Syndrome & Gallbladder Disease 14.5 Constipation, Hemorrhoids, Peptic Ulcer Disease & Other Upper and Lower GI Disorders

16 Chapter 15: Primary Care: Renal, Hematologic, Rheumatologic, Musculoskeletal & Dermatologic Health

15.1 Urinary Tract Infections, Pyelonephritis, Hematuria & Nephrolithiasis 15.2 Anemias in Women: Iron Deficiency, Microcytic & Macrocytic Anemias 15.3 Autoimmune & Rheumatologic Conditions: SLE, Antiphospholipid Syndrome, RA & Fibromyalgia 15.4 Musculoskeletal Complaints: Low Back Pain, Osteoarthritis, Sprains, Strains & Common Conditions in Women 15.5 Common Dermatologic Disorders in Women Across the Lifespan 15.6 Common Skin Conditions: Eczema, Contact Dermatitis, Psoriasis, Tinea, Vitiligo, Skin Lesions & Hidradenitis

17 Chapter 16: Neurologic, Mental Health, Behavioral & Psychosocial Care

16.1 Headache Disorders in Women: Migraine, Tension-Type, Red Flags & Hormonal Considerations 16.2 Depressive Disorders & Anxiety in Women Across the Reproductive Lifespan 16.3 Substance Use Disorders: Alcohol, Nicotine, Cannabis & Opioid Use in Women 16.4 Intimate Partner Violence (IPV), Sexual Assault & Trauma-Informed Care

18 Chapter 17: Assessment, Diagnostic Testing & Interpretation

17.1 Laboratory Diagnostics: Hematology, Coagulation, Chemistry, Hormone, Serologic & Screening Tests 17.2 Genetic Principles: Inheritance Patterns, Carrier Screening & Hereditary Cancer Risk Assessment 17.3 Gynecologic Office Diagnostic Procedures: Wet Mounts, Endometrial Biopsy & Colposcopy 17.4 Obstetric Diagnostic Imaging & Genetic Screening Modalities

19 Chapter 18: Pharmacology: Pharmacokinetics, Pharmacodynamics, Pharmacogenetics & Safe Prescribing

18.1 Clinical Pharmacokinetics Across the Female Lifespan & the FDA PLLR 18.2 Pharmacodynamics, Pharmacogenetics & Clinically Important Drug Interactions in Women's Health 18.3 Antimicrobial Stewardship & Pharmacotherapy in Pregnancy and Lactation

20 Chapter 19: Professional Role, Legal, Ethical, Quality & Health Equity Responsibilities

19.1 APRN Scope of Practice, Consensus Model & Collaborative Practice 19.2 Legal, Ethical & Informed Consent Issues in Reproductive Health Care 19.3 Evidence-Based Practice, Research Terminology, Quality Improvement & Patient Safety 19.4 Maternal Health Equity, Cultural Humility & Gender-Affirming Gynecologic Care

4.3 Amenorrhea Evaluation: Primary & Secondary Etiologies

Key Takeaways Explain This Topic AI

Primary amenorrhea is defined as the failure to achieve menarche by age 15 in the presence of normal secondary sexual characteristics (breast development), or by age 13 in the absence of secondary sexual characteristics; secondary amenorrhea is the cessation of menses for >=3 consecutive months in previously regular cycles or >=6 months in irregular cycles.

The diagnostic algorithm for primary amenorrhea begins with evaluating secondary sexual characteristics (breast development as a bioassay for systemic estrogen exposure) and transvaginal or transabdominal pelvic ultrasonography to confirm the presence or absence of a uterus.

Primary amenorrhea divides into four clinical categories: (1) breasts present/uterus present (outflow tract obstruction such as imperforate hymen or transverse vaginal septum); (2) breasts absent/uterus present (hypogonadotropic or hypergonadotropic hypogonadism, including Turner syndrome 45,X); (3) breasts present/uterus absent (Müllerian agenesis/MRKH 46,XX vs Complete Androgen Insensitivity Syndrome CAIS 46,XY); and (4) breasts absent/uterus absent (rare enzymatic defects).

Secondary amenorrhea evaluation follows a systematic stepwise cascade: first excluding pregnancy (hCG), thyroid disease (TSH), and hyperprolactinemia (prolactin); followed by a progestin challenge (medroxyprogesterone acetate 10 mg daily for 10 days) to assess endogenous estrogen and tract patency.

Patients failing to bleed after progestin withdrawal undergo an estrogen-progestin challenge: lack of bleeding confirms uterine outflow disruption (Asherman syndrome), whereas withdrawal bleeding followed by elevated FSH (>25 IU/L) confirms primary ovarian insufficiency (POI), and low/normal FSH points to functional hypothalamic amenorrhea (FHA) or pituitary pathology.

Last updated: October 2026

Amenorrhea Evaluation: Primary & Secondary Etiologies

Amenorrhea—the absence of menses—signals an endocrine, genetic, or anatomic disruption within the hypothalamic-pituitary-ovarian (HPO) axis or reproductive tract. Normal menarche occurs at a mean age of 12.4 years in the United States, preceded by an orderly pubertal cascade: thelarche (breast budding, Tanner 2, stimulated by ovarian estradiol), adrenarche/pubarche (adrenal androgenic pubic/axillary hair), peak height velocity (linear somatic growth), and menarche (typically 2 to 2.5 years after thelarche).

Important

Pregnancy is the leading cause of secondary amenorrhea and can occur prior to menarche in sexually active adolescents. A high-sensitivity urine or serum hCG test is the mandatory first step in any amenorrhea workup.

Clinical Definitions

Primary Amenorrhea:

Absence of menses by age 15 in an individual with normal growth and secondary sexual characteristics.

Absence of menses by age 13 in an individual who lacks secondary sexual characteristics (delayed puberty / hypogonadism).

Secondary Amenorrhea:

Absence of menses for >=3 consecutive months in an individual with previously regular menstrual cycles.

Absence of menses for >=6 consecutive months in an individual with a history of irregular oligomenorrhea.

Stepwise Primary Amenorrhea Diagnostic Algorithm

The evaluation of primary amenorrhea begins with two initial determinations: breast development (clinical bioassay of systemic estrogen exposure) and pelvic ultrasound (confirming the presence or absence of the uterus and cervix). Primary Amenorrhea

  • │
  • ┌───────────────────┴───────────────────┐
  • Breasts Present Breasts Absent
  • (Estrogen +) (Estrogen -)
  • │ │
  • ┌────────────┴────────────┐ ┌────────────┴────────────┐
  • Uterus Present Uterus Absent Uterus Present Uterus Absent
  • │ │ │ │
  • Outflow Obstruction: Differentiate: Measure Gonadotropins: Rare 46,XY steroid
  • Imperforate hymen • MRKH (46,XX) • High FSH: Turner biosynthesis defects
  • Transverse septum • CAIS (46,XY) (45,X; ovarian dys.) (17-alpha-hydroxylase)
  • Low/NL FSH: Kallmann,
  • FHA, CNS lesions
  • 1. Breasts Present, Uterus Present (Estrogen +, Uterus +)

Reflects an intact HPO axis and functional ovaries producing physiologic estradiol, with normal Müllerian organogenesis. The underlying pathology is an anatomic outflow tract obstruction :

Imperforate Hymen: Failure of the inferior vaginal plate to canalize. Adolescents present with cyclic pelvic pain, amenorrhea, urinary retention, and a bulging, bluish membrane at the introitus ( hematocolpos ). Managed with surgical hymenotomy .

Transverse Vaginal Septum: Failure of vertical fusion between Müllerian ducts and the urogenital sinus. Patients present with cyclic pain and hematometra, but examination reveals a blind vaginal pouch without an introital bulge. Evaluated by pelvic MRI and treated with surgical resection.

2. Breasts Absent, Uterus Present (Estrogen -, Uterus +)

Reflects failure of pubertal ovarian estrogen production, with intact Müllerian structures due to absence of anti-Müllerian hormone (AMH). Measure serum FSH and LH :

Hypergonadotropic Hypogonadism (Elevated FSH >30–40 mIU/mL, low estradiol): Primary gonadal failure / ovarian dysgenesis. Loss of follicular negative feedback causes elevated gonadotropins.

Turner Syndrome (45,X or mosaicism): The most common genetic cause (~50% of hypergonadotropic cases). Accelerated fetal atresia leaves fibrous "streak gonads." Features include short stature, webbed neck, shield chest, high-arched palate, and cardiac defects (coarctation of the aorta, bicuspid aortic valve). Karyotyping is mandatory. Management includes growth hormone and pubertal hormone replacement therapy.

Swyer Syndrome (46,XY pure gonadal dysgenesis): Phenotypic females with streak gonads and a uterus. Carries a 20%–30% risk of malignant germ cell tumors ( gonadoblastoma, dysgerminoma ); mandates prompt bilateral prophylactic gonadectomy.

Hypogonadotropic Hypogonadism (Low or normal FSH/LH, low estradiol): Central failure of GnRH or gonadotropins.

Kallmann Syndrome: Defective embryonic migration of GnRH neurons and olfactory axons. Classic triad: primary amenorrhea, absent puberty, and anosmia or hyposmia .

Functional Hypothalamic Amenorrhea (FHA): Chronic severe energy deficiency, extreme athletic training, or eating disorders in early adolescence.

Pituitary/Hypothalamic Tumors: Craniopharyngioma or prolactinoma. Requires contrast-enhanced brain MRI.

3. Breasts Present, Uterus Absent (Estrogen +, Uterus -)

Differentiate Müllerian Agenesis (MRKH) from Complete Androgen Insensitivity Syndrome (CAIS) :

  • Feature Müllerian Agenesis (MRKH Syndrome) Complete Androgen Insensitivity (CAIS)
  • Karyotype 46,XX (Genotypic female) 46,XY (Genotypic male)
  • Gonads Functional normal ovaries Undescended testes (inguinal, labial, intra-abdominal)
  • Serum Testosterone Normal female range (20–45 ng/dL) Normal male range (300–1,000 ng/dL)
  • Pubic & Axillary Hair Normal female distribution (Tanner 5) Sparse or completely absent (androgen-resistant)
  • Breast Development Normal female development Normal to large breasts; juvenile pale areolae
  • Anatomy Absent uterus, cervix, upper vagina Absent uterus, cervix, upper vagina (AMH regressed ducts)

Associated Findings Renal anomalies (30%–40%), spine defects (10%–15%) Low germ cell tumor risk before adulthood (about 1–2%), rising later

Management Vaginal dilation (Frank method) or vaginoplasty; renal US Bilateral gonadectomy post-puberty; estrogen therapy

4. Breasts Absent, Uterus Absent (Estrogen -, Uterus -)

Extremely rare 46,XY steroidogenesis defects (e.g., 17-alpha-hydroxylase deficiency, 17,20-lyase deficiency) where testes produced AMH (regressing Müllerian ducts) but failed to produce androgens or estrogens.

Secondary Amenorrhea Stepwise Diagnostic Cascade

Follow a structured 4-step sequence:

Step 1: Initial Essential Laboratory Evaluation

hCG: Exclude pregnancy.

TSH: Identify hypothyroidism (which elevates TRH, raising prolactin and disrupting GnRH) or hyperthyroidism.

Prolactin: Elevated prolactin suppresses GnRH. Review dopamine-blocking medications. If persistently elevated, obtain pituitary MRI.

Step 2: Progestin Withdrawal Challenge

Administer oral medroxyprogesterone acetate (MPA) 10 mg daily for 10 to 14 days :

Positive Withdrawal Bleed (bleeding within 2–7 days post-progestin): Confirms adequate endogenous estrogen priming the endometrium and a patent outflow tract. Diagnosis: Anovulation / Ovulatory Dysfunction (e.g., PCOS). Prescribe cyclical progestins, combined contraceptives, or LNG-IUS for endometrial protection.

Negative Withdrawal Bleed (no bleeding): Indicates anatomical disruption OR profound hypoestrogenism. Proceed to Step 3.

Step 3: Combined Estrogen-Progestin Challenge

Administer oral conjugated equine estrogens (CEE) 1.25–2.5 mg daily (or oral estradiol 2 mg daily) for 21 days, adding MPA 10 mg daily for the final 10 days :

Negative Challenge (No bleeding): Endometrium is unreactive or blocked -> Asherman Syndrome (intrauterine synechiae) or severe cervical stenosis. Typically follows vigorous sharp curettage during pregnancy or postpartum. Confirmed by hysteroscopy or saline infusion sonohysterography.

Positive Challenge (Withdrawal bleeding occurs): Endometrium and outflow tract are intact. Amenorrhea is due to hypoestrogenism . Proceed to Step 4.

Step 4: Gonadotropin Differentiation (FSH and LH)

Hypergonadotropic Hypogonadism (FSH >25 IU/L): Primary Ovarian Insufficiency (POI) in women <40 years. The 2024 ESHRE/ASRM guideline requires only one elevated FSH with at least 4 months of disordered cycles; repeat in 4–6 weeks only if the diagnosis is uncertain. Evaluate for autoimmune oophoritis (21-hydroxylase antibodies), Fragile X ( FMR1 premutation), and karyotype anomalies.

Hypogonadotropic Hypogonadism (Low or normal FSH <5–10 mIU/mL, low LH):

Functional Hypothalamic Amenorrhea (FHA): Relative Energy Deficiency in Sport (RED-S), low energy availability, disordered eating, or severe psychological stress suppressing hypothalamic kisspeptin and GnRH.

Sheehan Syndrome: Postpartum pituitary ischemic necrosis from massive obstetric hemorrhage; presents with failure to lactate (agalactorrhea) and amenorrhea.

Long-Term Health Consequences & Management

Profound hypoestrogenism in POI and chronic FHA accelerates bone resorption, causing early osteopenia and osteoporosis. It also promotes endothelial dysfunction and adverse lipid profiles.

Hormone Replacement Therapy (HRT): Physiological hormone replacement (transdermal estradiol 100 mcg patch daily + oral micronized progesterone 200 mg nightly 12–14 days/month) is mandatory until the median age of natural menopause (age 51) .

Bone Support: DEXA scan, elemental calcium (1,200 mg daily), and vitamin D3 (800–1,000 IU daily).